Drotrecogin alfa (activated) is a recombinant form of human activated protein C that has anti-thrombotic, anti-inflammatory, and profibrinolytic properties.
Easy to read patient leaflet for drotrecogin alfa. Includes indications, proper use, special instructions, precautions, and possible side effects.
Drotrecogin alfa (activated) (Xigris, Eli Lilly and Company, Indianapolis, Ind) is a recombinant form of human activated protein C. It was approved by the Food ...
May 22, 2012 ... There have been conflicting reports on the efficacy of recombinant human activated protein C, or drotrecogin alfa (activated) (DrotAA), for the ...
Oct 31, 2016 ... Xigris (drotrecogin alfa (activated)) is a recombinant form of human activated protein C. An established human cell line possessing the ...
Oct 25, 2011 ... October 25, 2011 — Eli Lilly is withdrawing activated drotrecogin alfa (Xigris), a drug intended to treat severe sepsis in high-risk patients, from ...
Jun 13, 2005 ... Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 ...
Drotrecogin alfa [recombinant Human Activated Protein C (Xigris™)], was recently approved by the FDA for the reduction of mortality in adult patients with severe ...
Oct 25, 2011 ... FDA Drug Safety Communication: Voluntary market withdrawal of Xigris [ drotrecogin alfa (activated)] due to failure to show a survival benefit.
Drug information on Xigris (drotrecogin alfa), includes drug pictures, side effects, drug interactions, directions for use, symptoms of overdose, and what to avoid.